CBT
SRPT icon

Capital Bank & Trust’s Sarepta Therapeutics SRPT Stock Holding History

Capital Bank & Trust’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8
Closed -$1K – 600
2020
Q1 		$1K Buy
+8
New +$914 ﹤0.01% 675

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Bank & Trust's SRPT Position: Q2 2020 in Review

Capital Bank & Trust sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 8 shares — an estimated $1K sold.

Capital Bank & Trust first reported a position in SRPT in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 408 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

  • Capital Bank & Trust reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Capital Bank & Trust sold 8 Sarepta Therapeutics shares in Q2 2020, an estimated $1K.
  • Capital Bank & Trust first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 1 quarter.
  • Capital Bank & Trust's Sarepta Therapeutics position peaked at $1K in Q1 2020.
  • 408 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.